Helus Pharma's HLP004 Phase 2 Study Results Disappoint
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy HELP?
Source: Benzinga
- Clinical Trial Results: Helus Pharma's HLP004 Phase 2 signal detection study involved 36 patients randomized to receive either HLP004 or a placebo, showing a 10.4-point improvement in anxiety symptoms beyond standard care, yet failing to significantly boost market confidence.
- Good Tolerability: The drug exhibited a favorable tolerability profile with no drug-related serious adverse events or suicidality-related safety signals, providing a foundation for future clinical applications, but not alleviating market concerns regarding its efficacy.
- Response Rate Analysis: After six months, 67% of participants showed a response and 39% achieved remission, with the 20mg group having a 59% response rate and the 2mg group at 30%, although the positive data did not prevent a significant market downturn, leading to a sharp drop in stock price.
- Poor Market Performance: Helus Pharma shares fell 33.19% to $6.41 at publication, trading well below both the 20-day and 100-day simple moving averages, indicating a bearish trend in the short term, as investors remain cautious about future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HELP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HELP
Wall Street analysts forecast HELP stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.740
Low
22.00
Averages
41.17
High
55.00
Current: 5.740
Low
22.00
Averages
41.17
High
55.00
About HELP
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that patients receiving the 20 mg dose achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential as an adjunctive treatment for generalized anxiety disorder.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of major depressive disorder patients being treatment-resistant, driving urgent demand for novel therapeutic mechanisms that Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline and safeguarding its research activities in the mental health sector from financial constraints.
- Enhanced Leadership: The appointment of Dr. Freda Lewis-Hall to Helus Pharma's Board and as Chair of the Scientific Advisory Committee, leveraging her extensive experience at Pfizer, is expected to provide crucial guidance for the company's scientific development and market strategy.
See More
Helus Pharma's Anxiety Drug Trial Results Trigger Stock Plunge
- Clinical Trial Results: Helus Pharma's anxiety drug HLP004 showed a 10.4-point drop in anxiety scores after six weeks in a 36-patient mid-stage trial, with 67% of participants responding to treatment; however, the results fell short of market expectations, causing a 34% plunge in stock price to $5.64, marking a record low.
- Market Reaction Analysis: Despite the negative trial results for HLP004, Jefferies maintained a 'Buy' rating on Helus Pharma with a $22 price target, implying a 290% upside from current levels, reflecting confidence in the company's future potential.
- Future Catalysts: Jefferies highlighted that, although the anxiety drug trial results were disappointing, Helus Pharma's lead drug HLP003 for major depressive disorder could serve as a larger catalyst, with Phase 3 trial results expected in Q4 2026, potentially driving stock surges of 100% to 200%.
- Investor Sentiment: On Stocktwits, despite HELP's 31% year-to-date decline, retail sentiment remains 'extremely bullish', with investors believing that the upcoming Phase 3 trials will be pivotal, indicating market optimism regarding Helus Pharma's long-term prospects.
See More
US Stock Futures Stabilize Amid Oil Price Surge
- Market Volatility Intensifies: The Dow Jones Industrial Average plummeted nearly 800 points on Thursday, closing down 1.6%, while the S&P 500 and Nasdaq Composite fell 0.6% and 0.3% respectively, indicating heightened market sensitivity to geopolitical tensions and surging oil prices.
- Oil Price Surge Impact: Following an Iranian missile strike on an oil tanker, West Texas Intermediate crude surged 8.5% to $81.01 per barrel, marking its highest level since 2024, which triggered sharp swings in equity markets, with the Dow briefly dropping over 1,100 points, reflecting the high uncertainty in energy markets.
- Diverging Investor Sentiment: Despite the overall market decline, Berkshire Hathaway's stock rose nearly 3% as it announced its first stock buyback since 2024, with CEO Greg Abel purchasing about $15 million in company stock, demonstrating confidence in the company's future.
- Asia-Pacific Market Decline: Asian stocks fell broadly, with the MSCI Asia Pacific Index down about 0.6%, reflecting a cumulative decline of 6.7% since the onset of the war, as investors remain concerned about the global economic outlook, especially ahead of upcoming U.S. employment and retail sales data.
See More
Helus Pharma's HLP004 Phase 2 Study Results Disappoint
- Clinical Trial Results: Helus Pharma's HLP004 Phase 2 signal detection study involved 36 patients randomized to receive either HLP004 or a placebo, showing a 10.4-point improvement in anxiety symptoms beyond standard care, yet failing to significantly boost market confidence.
- Good Tolerability: The drug exhibited a favorable tolerability profile with no drug-related serious adverse events or suicidality-related safety signals, providing a foundation for future clinical applications, but not alleviating market concerns regarding its efficacy.
- Response Rate Analysis: After six months, 67% of participants showed a response and 39% achieved remission, with the 20mg group having a 59% response rate and the 2mg group at 30%, although the positive data did not prevent a significant market downturn, leading to a sharp drop in stock price.
- Poor Market Performance: Helus Pharma shares fell 33.19% to $6.41 at publication, trading well below both the 20-day and 100-day simple moving averages, indicating a bearish trend in the short term, as investors remain cautious about future prospects.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that patients receiving the 20 mg dose achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential as an adjunctive treatment for generalized anxiety disorder.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of major depressive disorder patients being treatment-resistant, driving urgent demand for novel therapeutic mechanisms that Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline and safeguarding its research activities in the mental health sector from financial constraints.
- Enhanced Leadership: The appointment of Dr. Freda Lewis-Hall to Helus Pharma's Board and as Chair of the Scientific Advisory Committee, leveraging her extensive experience at Pfizer, is expected to provide crucial guidance for the company's scientific development and market strategy.
See More
Helus Pharma's Anxiety Drug Trial Results Trigger Stock Plunge
- Clinical Trial Results: Helus Pharma's anxiety drug HLP004 showed a 10.4-point drop in anxiety scores after six weeks in a 36-patient mid-stage trial, with 67% of participants responding to treatment; however, the results fell short of market expectations, causing a 34% plunge in stock price to $5.64, marking a record low.
- Market Reaction Analysis: Despite the negative trial results for HLP004, Jefferies maintained a 'Buy' rating on Helus Pharma with a $22 price target, implying a 290% upside from current levels, reflecting confidence in the company's future potential.
- Future Catalysts: Jefferies highlighted that, although the anxiety drug trial results were disappointing, Helus Pharma's lead drug HLP003 for major depressive disorder could serve as a larger catalyst, with Phase 3 trial results expected in Q4 2026, potentially driving stock surges of 100% to 200%.
- Investor Sentiment: On Stocktwits, despite HELP's 31% year-to-date decline, retail sentiment remains 'extremely bullish', with investors believing that the upcoming Phase 3 trials will be pivotal, indicating market optimism regarding Helus Pharma's long-term prospects.
See More
US Stock Futures Stabilize Amid Oil Price Surge
- Market Volatility Intensifies: The Dow Jones Industrial Average plummeted nearly 800 points on Thursday, closing down 1.6%, while the S&P 500 and Nasdaq Composite fell 0.6% and 0.3% respectively, indicating heightened market sensitivity to geopolitical tensions and surging oil prices.
- Oil Price Surge Impact: Following an Iranian missile strike on an oil tanker, West Texas Intermediate crude surged 8.5% to $81.01 per barrel, marking its highest level since 2024, which triggered sharp swings in equity markets, with the Dow briefly dropping over 1,100 points, reflecting the high uncertainty in energy markets.
- Diverging Investor Sentiment: Despite the overall market decline, Berkshire Hathaway's stock rose nearly 3% as it announced its first stock buyback since 2024, with CEO Greg Abel purchasing about $15 million in company stock, demonstrating confidence in the company's future.
- Asia-Pacific Market Decline: Asian stocks fell broadly, with the MSCI Asia Pacific Index down about 0.6%, reflecting a cumulative decline of 6.7% since the onset of the war, as investors remain concerned about the global economic outlook, especially ahead of upcoming U.S. employment and retail sales data.
See More
Helus Pharma's HLP004 Phase 2 Study Results Disappoint
- Clinical Trial Results: Helus Pharma's HLP004 Phase 2 signal detection study involved 36 patients randomized to receive either HLP004 or a placebo, showing a 10.4-point improvement in anxiety symptoms beyond standard care, yet failing to significantly boost market confidence.
- Good Tolerability: The drug exhibited a favorable tolerability profile with no drug-related serious adverse events or suicidality-related safety signals, providing a foundation for future clinical applications, but not alleviating market concerns regarding its efficacy.
- Response Rate Analysis: After six months, 67% of participants showed a response and 39% achieved remission, with the 20mg group having a 59% response rate and the 2mg group at 30%, although the positive data did not prevent a significant market downturn, leading to a sharp drop in stock price.
- Poor Market Performance: Helus Pharma shares fell 33.19% to $6.41 at publication, trading well below both the 20-day and 100-day simple moving averages, indicating a bearish trend in the short term, as investors remain cautious about future prospects.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
